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ABSTRACT 
Approximately 25 years ago, our team initiated studies to determine whether outcome results 
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from a large medical record database would yield valid results. We utilized the data in the United Kingdom 
(UK) General Practice Research Database (GPRD) to replicate the randomized controlled trial (RCT) study 
result and compared them to confirm the database results. The initial studies compared favorably, but 
some subsequent studies did not. This prompted development of a new strategy to determine and correct 
for unrecognized confounding in the database. This strategy divided outcome rates prior to initiation of 
therapy in the database study (which should include both identified and unidentified confounders) into 
the outcome rates during the treatment interval. When they differed from Cox adjusted results, it 
reflected unrecognized confounding. We called this strategy Prior Event Rate Ratio (PERR) adjusted 
outcome. 
One of our previously published observational studies replicated the Women’s Health Initiative 
(WHI) RCT study of hormone therapy in post-menopausal women. Our study results replicated the WHI 
RCT results except it did not exhibit an increase in heart attack in contrast to the RCT. Furthermore, we 
could not evaluate death reliably since our analytic approach to overcome unrecognized confounding does 
not work for this outcome. In Volume 1, Issue 1 of the Learning Health Systems open access journal, we 
published a new study (titled “A new method to address unmeasured confounding of mortality in 
observational studies”) that reported a novel death method, based on our prior methodology, that could 
analyze unrecognized confounding of the death outcome. This new methodology, termed Post Treatment 
Event Rate Ratio (PTERR), permitted a reliable examination of mortality in postmenopausal women 
undergoing hormone therapy. These results are reported in this manuscript. The study used the data from 
our previous observational study. It demonstrates that estrogen therapy markedly reduced death in post- 
menopausal women. 
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This work also illuminates principles of database construction and correspondingly demonstrates 
the use of novel methodologies for obtaining valid results, which can be applied to enable learning from 
such databases. Work to advance such methodologies is essential to advancing the scientific integrity Core 
Value underpinning Learning Health Systems (LHSs). Indeed, in the absence of such efforts to develop and 
refine methodologies for learning trustworthy lessons from real-world data, we risk inadvertently creating 
mis-learning systems. 
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INTRODUCTION 
The benefits of hormonal therapy for menopausal women have been debated for decades. The 
health benefits of hormonal therapy have been hypothesized, refuted, and re-hypothesized. The risk and 
benefits for specific outcomes such as cardiovascular disease, cancer, or osteoporosis are often 
contradictory. However, despite the large amount of data on this subject, we are not able to evaluate 
mortality. 
The Women’s Health Initiative (WHI) was a large and important Randomized Controlled Trial (RCT) 
study. Subgroup analysis of the WHI RCT provided a hint that combined estrogen-progestin (EPT) therapy 
or estrogen (ET) therapy itself might decrease mortality in younger women (ages 50-60) [1-3]. However, 
these results did not achieve statistical significance. Furthermore, secondary subgroup analysis could be 
distorted by unrecognized confounding, because subgroup analysis is similar to an observational study 
rather than an RCT. 
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Our prior observational studies which replicated the WHI RCT using the United Kingdom (UK) 
General Practice Research Database (GPRD) database also found a decrease in mortality with both ET and 
EPT therapy in women ages 50-54 and 55-79 [4-7]. Other outcomes in these studies could be corrected for 
unrecognized confounding by a new technique we developed called Prior Event Rate Ratio (PERR) [8,9]. 
PERR analysis is a tool to identify and quantitate unrecognized confounding for many outcomes; it involves 
analysis of outcomes in the time period preceding the therapy period, and is then applied to the data 
during the analytic period. However, this strategy could not be applied to mortality (which cannot be a 
prior event). Therefore, we could not conclude with certainty that mortality was reduced. 
Recently, we published new studies which suggest that a strategy similar to PERR appears to 
overcome unrecognized confounding for mortality [10]. In Volume 1, Issue 1 of the Learning Health Systems 
open access journal, we published a new study (titled “A new method to address unmeasured 
confounding of mortality in observational studies”) that discussed how this novel methodology, termed 
Post Treatment Event Rate Ratio (PTERR), permitted a reliable examination of mortality in 
postmenopausal women undergoing hormone therapy. PTERR analysis applies an approach analogous to 
PERR analysis, but for the post treatment period, permitting the study of the death outcome. As part of 
our process for applying these methods, the WHI replication studies were included in these studies, and 
this manuscript expands upon these findings. This work and its implications will subsequently be further 
discussed. 
Beyond the specific findings, our work also serves to advance the development of methodologies 
for learning trustworthy lessons from real-world data, which is an important component of Learning 
Health Systems (LHSs). One of the multi-stakeholder consensus Core Values of LHSs is scientific integrity--
This article is protected by copyright. All rights reserved.
5 
 
 
rigorously applying science to ensure validity and credibility of findings. In a similar vein, communities 
working to Mobilize Computable Biomedical Knowledge have emphasized in their founding principles the 
paramount importance of ensuring that such knowledge can be trusted to improve health and health care; 
communities working to advance policies, practice, and research related to the Ethical, Social, and Legal 
Implications (ELSI) of LHSs also underscore the trust factor, grounded in part in the rigorous application of 
scientific methods. Federal government agencies and key nonprofit organizations supporting research to 
advance LHSs, including the Patient-Centered Outcomes Research Institute (PCORI), have convened 
methodology committees and invested in synergistic efforts to advance the development of 
methodologies to learn trustworthy lessons from (every) data. More generally, LHSs are anchored in a 
common cultural commitment to learn and improve from (every) experience, and in doing so, LHSs also 
share an implicit value for continuously learning how to learn better. Our work here to build upon the 
PERR analysis method, and to develop, test, and refine the PTERR method on an outcome we had not 
previously had the capacity to study, all work to advance such methodological development and 
refinement. This scientific methodological research, along with our other publications, collectively 
emphasize that appropriately constructed medical databases, along with proper analysis of the data they 
contain, promise to advance medicine. Our ability to analyze most outcomes, and now mortality, and to 
overcome potential unrecognized confounding in doing so, has propelled database construction and 
analysis into a major tool for advancing clinical research and clinical medicine. 
 
KEY ACRONYMS 
• GPRD = General Practice Research Database 
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• HR = Hazard Ratio 
• LHSs = Learning Health Systems 
• PCORI = Patient-Centered Outcomes Research Institute 
• PERR = Prior Event Rate Ratio 
• PTERR = Post Treatment Event Rate Ratio 
• RCT = Randomized Controlled Trial 
• WHI = Women’s Health Initiative 
 
METHODS 
The initial database replications of the WHI RCT included subjects from ages 50 to 79 years old. 
First Exposed subjects were selected from those that met the entry criteria for the RCT and were being 
treated with either conjugated estrogen and progestin (norgestrel) if they had an intact uterus and no 
progestin if they had a prior hysterectomy. Start time for the exposed subjects was defined by when 
therapy began during a predetermined recruitment interval. Then, the unexposed subjects were matched 
to the exposed subjects by age using a random computer matching technique and were assigned the same 
start time as the matched exposed subject. 
The original cohorts that included subjects aged 50 to 79 were then subdivided into two groups 
(ages 50 to 54) and (55 to 79) years. The older group more closely matched the age of the RCT, and the 50 
to 54 group encompassed a younger cohort than the RCT. Two different types of analytics were employed 
to assess outcomes of the database studies. In the first type, analyses were performed using a simulated 
intention-to-treat analysis where a fixed end time was set and subjects were followed until they dropped 
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out of the database, died, or reached a predetermined end time. In the second type, an as-treated analysis 
was performed where, in addition to the above criteria, the subject’s study ended if the post-menopausal 
drug treatment was altered. 
The database study outcomes hazard ratios were analyzed using Cox unadjusted and adjusted 
results and compared to the RCT event results. Database results also were analyzed using the PERR 
method to overcome unrecognized confounding, and these results for stroke and acute myocardial 
infarction were compared with both the Cox adjusted and the RCT results [7]. Prior Event Rate adjustment 
compared outcomes before study entry, when neither the exposed or the unexposed cohorts were taking 
medications. Theoretically, this should delineate the aggregate effect of all confounders (both measured 
and unmeasured) on an outcome. Dividing the Hazard Ratio (HR) of an outcome during the study by the 
PERR HR should the result in a value similar to the Cox adjusted HR if there is no unmeasured 
confounding. The validity of this approach has been substantiated by comparisons of database and RCT 
outcome results and also by theoretical analyses of the method [8,9]. Mortality cannot be examined by this 
method, because death prior to study entry would eliminate entry into the study. 
A new method (PTERR) was developed to address unmeasured confounding of mortality of the 
death rate after the treatment interval in a fashion similar to the PERR use of the outcome rate prior to 
study [10]. Our prior database studies were used to test the validity of this method. This strategy was 
feasible because all database studies were analyzed using both “intention-to-treat” and "as-treated" 
analyses. Since the “intention-to-treat” analysis often had a duration longer than the “as-treated” analysis, 
a post- treatment time period could be delineated for the exposed cohort. Because the unexposed cohort 
subjects were matched by start time to the exposed subjects, their duration could be altered similar to the 
This article is protected by copyright. All rights reserved.
8 
 
 
matched subjects comparison of a similar “post-treatment” period. As noted in the published manuscript, 
this new method appears to yield valid results, albeit that it could not be verified with the same rigor as 
the PERR method [10]. One of the prior studies evaluated by this method was the database replication of 
the WHI RCT [4]. The striking results for mortality in this analysis led to publication of this manuscript. We 
designed the database mortality results to be for the same age groups as the WHI secondary study, which 
encompassed women 50 to 60 and 50  to 70 years of age. 
 
SUMMARY OF METHODOLOGIES DEVELOPED 
• Prior Event Rate Ratio (PERR) analysis is a tool we developed to identify and quantitate 
unrecognized confounding for many outcomes; it involves analysis of outcomes in the time period 
preceding the therapy period, and is then applied to the data during the analytic period. 
• Post Treatment Event Rate Ratio (PTERR) analysis is a tool we developed specifically to identify 
and quantitate unrecognized confounding for the death outcome, applying an approach 
analogous to PERR analysis, but for the post treatment period. 
 
RESULTS 
The comparisons between the RCT Intact uterus and hysterectomy studies and the database 
PTERR correction results for these studies are shown in Table 1. The details regarding the death analysis of 
the database studies are shown in Table 2. The results for mortality from the WHI RCT intact uterus and 
hysterectomy studies were compared with database study results of women in the same age brackets (50-
60 years and 50-70 years). The intact uterus and hysterectomy results for the WHI RCT for the 50 to 60- 
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year-old cohort showed a decrease in mortality in the treated group, which was not significant statistically. 
The database studies of this same age group demonstrated a decrease in mortality which achieved 
statistical significance but did not exhibit statistical significance in comparison to the WHI RCT results. It 
should be noted that the size of the cohorts in the database study was markedly larger than the cohorts in 
the secondary analysis of the WHI RCT. 
The intact uterus and hysterectomy results for the WHI RCT for the 50 to 70-year-old cohorts did 
not exhibit a decrease in mortality. By contrast, the results for this age group in both the database studies 
exhibited a significant decrease in mortality that was also significantly lower than the results in the RCT 
study. It is important to note that the size of the cohorts in the database studies was dramatically higher 
than the secondary RCT studies. 
In our prior publication, death was decreased significantly in both older (55-79) and younger (50- 
54) women in both the intact uterus study (estrogen and progesterone) and the hysterectomy study 
(estrogen only) [7]. There was a hint, however, that cohorts without missing data on baseline confounders 
(BMI BP & smoking) did not exhibit as large a decrease in death. We revisited this issue using our current 
data on death using cohorts from both the intact uterus and also hysterectomy cohorts. These studies 
were performed on subjects aged 50 to 70 with no missing confounders. The results for these “no 
missing” studies are shown in Table 3. In comparison to the results of the studies with missing data on 
baseline confounders shown in Table 2, there are no meaningful differences. 
 
DISCUSSION 
Our replication of the WHI RCT provides a deeper insight to support the striking decrease in 
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mortality for women treated with estrogen hormone replacement therapy during menopause. Estrogen is 
clearly identified as the medication responsible for this effect, since women who ingested both estrogen 
and progesterone exhibited decreases in mortality similar to those who ingested only estrogen. 
The methods utilized aimed to address the potential for unrecognized confounding. Such an 
approach can be compared with other previous studies. For instance, the secondary subgroup analysis of 
the WHI RCT tends to support this finding, but the cohorts were too small to achieve statistically 
meaningful results and also suffer from the possibility of unrecognized confounding [1]. The meta-analysis 
by Salpeter and colleagues found a decrease in mortality in women with the mean age of <60 years, but 
not in older women. Furthermore, it does not identify estrogen as the protective medication and also is 
subject to unrecognized confounding [11]. Mikkola et al used data from the nationwide reimbursement 
register and the Cause of Death Register of Finland for their studies of post-menopausal hormone therapy 
[12]. They reported a decrease in death from treatment with estradiol and/or progesterone treatment 
along with a decrease in coronary heart disease, stroke, or other causes of mortality. However, this 
database study did directly not address the possibility of unrecognized confounding. 
How post-menopausal estrogen accounts for the prevention of death is not delineated by our 
study. Both the WHI RCT and our database study examined other outcomes that can provide some clue as 
to potential ways in which estrogen can in protect against death. Both the RCT and the database study 
found an increase in stroke, no reduction in acute myocardial infarction, an increase in breast cancer, and 
an increase in events related to venous clotting in subjects treated with estrogen. Estrogen did result in a 
decrease in colon cancer and also a decrease in hip fracture, but the degree of protection seems unlikely 
to have resulted in the magnitude of the decline in mortality. Thus, the basis for the protective effect of 
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estrogen therapy remains unexplained. Nevertheless, our findings strongly support the use of post-
menopausal estrogen therapy. 
More generally, this work demonstrates the potential of the PTERR analysis method, building 
upon the PERR analysis method, to help illuminate valid and trustworthy lessons that can be learned from 
real-world health data derived from properly constructed medical databases. Doing so promises to 
stimulate further discussion of and research into methodologies grounded in the scientific integrity Core 
Value of LHSs, that is so paramount to building trustworthiness and engendering trust in the lessons 
learned in LHSs aimed at improving health, as well as in the LHSs themselves. 
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TABLES 
 
TABLE 1. RCT vs DATABASE RESULTS 
 N N HR (95% CI) P vs RCT 
 CASE CONTROL   
INTACT UTERUS     
RCT     
     AGE 50-60 2839 2683 0.69 (0.44-1.07)  
     AGE 50-70 6692 6340 0.98 (0.77-1.25)  
DATABASE   PTERR adja  
     AGE 50-60 29,972 51,584 0.39 (0.29-0.50) NS 0.03 
     AGE 50-70 34,006 64,226 0.38 (0.31-0.48) <0.01 
     
HYSTERECTOMY     
RCT     
     AGE 50-60 1,637 1,673 0.71 (0.46-1.11)  
     AGE 50-70 4,024 4,128 0.94 (0.75-1.16)  
DATABASE  adjusted PTERR adja  
     AGE 50-60 10,802 15,902 0.44 (0.28-0.70) NS 0.14 
     AGE 50-70 13,659 20,206 0.39 (0.28-0.54) <0.01 
 
* Table 1. Footnotes: 
a. Post Treatment Event Rate Ratio Adjusted 
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TABLE 2. DATABASE STUDY RESULTS 
 AS TREATED 
PERIOD 
N 
COX 
UNIVARIABLE 
(95% CI) 
HR/95% CI 
COX 
MULTIVARIABLE 
(95% CI) 
HR/95% CI 
PTERR ADJ 
(95% CI) 
HR/95% CI 
COX 
MULTIVARIABLE 
vs PTERR ADJa 
P-VALUE 
POST RX 
PERIOD 
PTERRb 
HR/95% CI 
INTACT UTERUS 
STUDY 
      
AGE 50-70     0.01  
EXPOSED 34,006 0.38 0.55 0.38  0.99 
UNEXPOSED 64,226 (0.29-0.50) (0.46-0.62) (0.31-0.48)  (0.85-1.16) 
AGE 50-60     0.27  
EXPOSED 29,972 0.42 0.55 0.39  1.08 
UNEXPOSED 51,584 (0.36-0.49) (0.47-0.66) (0.29-0.50)  (0.89-1.31) 
       
HYSTERECTOMY 
STUDY 
      
AGE 50-70     NS  
EXPOSED 13,659 0.37 0.44 0.39  1.02 
UNEXPOSED 20,206 (0.30-0.46) (0.35-0.54) (0.28-0.54)  (0.79-1.31) 
AGE 50-60     NS  
EXPOSED 10,802 0.38 0.43 0.44  0.86 
UNEXPOSED 15,902 (0.29-0.50) (0.26-0.65) (0.28-0.70)  (0.61-1.20) 
 
* Table 2. Footnotes: 
aPost Treatment Event Rate Ratio adjusted 
bPost Treatment Event Rate Ratio 
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TABLE 3. NO MISSING BASE LINE DATA (SMOKING, SBP, BMI) 
 SUBJECTS 
N 
DEATH 
AS RX 
N / % 
POST 
SUBJECTS 
N 
DEATH 
POST 
N/% 
AS RX 
HR 
POST 
RX 
HR 
PTERR 
ADJa 
HR 
INTACT 
UTERUS 
STUDY 
       
AGE 50-70     0.487 1.094 0.44 
(0.35-0.59) 
EXPOSED 26,690 183 
(0.69%) 
11,023 183 
(1.66%) 
   
UNEXPOSED 39,253 391 
(1.00%) 
13,863 261 
(1.88%) 
   
        
HYSTERECTOMY 
STUDY 
       
AGE 50-70     0.381 1.099 0.35 
(0.27-0.44) 
EXPOSED 9,250 68 
(0.74%) 
3,420 69 
(2.02%) 
   
UNEXPOSED 12,029 137 
(1.14%) 
3,404 78 
(2.29%) 
   
 
* Table 3. Footnotes: 
aPost Treatment Event Rate Ratio adjusted 
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